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Available online 3 May 2009Drugs that bind to imidazoline binding proteins have major physiological actions. To date,
three subtypes of suchproteins, I1, I2 and I3, have beenproposed, although characterisationsof
these binding proteins are lacking. I2 binding sites are found throughout the brain, particularly
dense in the arcuate nucleus of the hypothalamus. Selective I2 ligands demonstrate
antidepressant-like activity and the identity of the proteins that respond to such ligands
remained unknown until now. Here we report the isolation of a ∼45 kDa imidazoline binding
protein from rabbit and rat brain using a high affinity ligand for the I2 subtype, 2-BFI, to
generate anaffinity column. Followingproteinsequencingof the isolated∼45kDa imidazoline
binding protein, we identified it to be brain creatine kinase (B-CK). B-CK shows high binding
capacity to selective I2 ligands; [3H]-2-BFI (5 nM) specifically bound to B-CK (2330±815 fmolmg
protein−1). We predicted an I2 binding pocket near the active site of B-CK using molecular
modelling. Furthermore, B-CK activitywas inhibited by a selective I2 irreversible ligand,where
20 μMBU99006 reduced the enzyme activity by 16%, confirming the interaction between B-CK
and the I2 ligand. In summary, we have identified B-CK to be the∼45 kDa imidazoline binding
protein andwe have demonstrated the existence of an I2 binding sitewithin this enzyme. The
importance of B-CK in regulating neuronal activity and neurotransmitter release may well
explain the various actions of I2 ligands in brain and the alterations in densities of I2 binding
sites in psychiatric disorders.
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and liver where they regulate monoamine turnover (Alemany
et al., 1997). The I3 sites are located in pancreatic β-cells and
these regulate insulin secretion (Chan et al., 1994). The
physiological relevance of these sites is strengthened by the
findings that endogenous substances especially agmatine (Li
et al., 1994) and harmane (Hudson et al., 2001) have significant
activity at one or more of these sites. Furthermore, ligands
targeting these sites demonstrate therapeutic potentials in
psychiatric disorders (Smith et al., 2009).
In order to advance our knowledge of properties of I2
binding proteins, several selective ligands were synthesised
including 2-(2-benzofuranyl)2-imidazoline (2-BFI), 2-(4,5-
dihydroimidaz-2-yl)quinoline (BU224) andan irreversible ligand
5-isothiocyanoato-2-benzofuranyl-2-imidazoline (BU99006)
(Fig. 1). These ligands have established the distribution of I2
sites;most interestingly, the density of I2 sites is extremely high
in the arcuate nucleus in rat brain (Lione et al., 1998).
Understanding the nature of I2 sites is important for a
number of reasons. Ligands selective for I2 sites have been
shown to regulate the release of biogenic amines such as
dopamine and noradrenaline and probably through these
mechanisms, they demonstrate antidepressant-like properties
(Finn et al., 2003). Furthermore, post-mortem studies have
shown that the density of I2 sites was altered in suicide/
depression and increased in Alzheimer's disease (García-
Sevilla et al., 1996, 1998), whereas there was a profound loss
of these sites in the basal ganglia of patients with Huntington's
disease (Reynolds et al., 1996). Moreover, brain I2 sites are
down-regulated in opiate dependence both in rat and human
(Hudson et al., 1996; Sastre et al., 1996). In addition, selective I2
ligands promote food intake (Nutt et al., 1995), which is
presumed to be an effect through the arcuate nucleus of the
hypothalamus since this brain region has a markedly high
density of I2 sites (Lione et al., 1998).
The identity of imidazoline binding proteins has attracted
interests of many research groups; however, determining its
identity has proven challenging. It is only recently that anFig. 1 – Chemical structures of selective I2 ligands.imidazoline binding protein of the I1-subtype was proposed to
be a receptor that belongs to the sphingosine-1-phosphate
(S1P)-receptor family (Molderings et al., 2007). For the I2-
subtype, the high abundance of I2 sites in liver led to an
exploration of monoamine oxidase as the possible I2 binding
protein over a decade ago. Subsequently, it was reported that
both monoamine oxidase (MAO) isoenzymes (A and B) show a
low affinity binding site for I2 ligands (Parini et al., 1996) and
that the nature of interaction was competitive (Ozaita et al.,
1997; Jones et al., 2007). However, the distribution of I2 site is
not contiguous with the distribution of MAO A or B (Eglen
et al., 1998) and discrepancies in the pharmacological profiles
regarding the interaction between MAO and I2 ligands (Ozaita
et al., 1997) indicated that there must be other proteins that
contain I2 binding domains. To date, a number of I2 binding
proteins have successfully been isolated and their existence as
a heterogeneous population has strongly been suggested
(Escribá et al., 1999). However, a definitive I2 binding protein
has yet to be identified; although, a ∼45 kDa protein has
previously been isolated from rat brain (Escribá et al., 1995)
and other studies have shown the expression of this protein is
altered in Alzheimer's disease and depression (García-Sevilla
et al., 1996, 1998).
The aim of this study was to isolate the ∼45 kDa binding
protein from rabbit and rat brain, and determine its identity.
We utilised a highly selective I2 ligand, 2-BFI, as a key tool in
affinity chromatography and employed N-terminal protein
sequencing to reveal the identity of the isolated protein.
Subsequently, we confirmed properties of this protein as an I2
binding protein using biochemical and pharmacological
techniques.2. Results
2.1. Isolation of I2 binding proteins using 2-BFI affinity
column
Rabbit or rat brain I2 binding proteins were solubilised,
loaded onto the 2-BFI affinity column and then eluted off
using idazoxan (20 mM). The isolated proteins were con-
centrated and subjected to SDS-PAGE analysis for further
separation according to their molecular weight. Coomassie
Blue staining revealed a strong band at ∼45 kDa together
with several weaker bands of various sizes (Fig. 2). This
∼45 kDa band was absent from the control column, in which
2-BFI was not linked to the matrix, indicating specific
binding of this protein to 2-BFI (Fig. 2). The proteins
separated by SDS-PAGE analysis were transferred onto
PVDF membranes. The ∼45 kDa band was excised and
subjected to N-terminal sequencing. The resulting peptide
contained a ten amino acid sequence of -PFSNTHNTLK-. This
sequence was used to search for the identity of this protein
in a protein sequence database (Protein Information
Resources, Wu et al., 2002). The exact match for the ten
amino acid sequence of rabbit brain origin was confirmed as
rabbit brain creatine kinase (B-CK, 43 kDa, EC 2.7.3.2); the
match was found at the N-terminus of this enzyme.
Extensive search of the identified peptide in protein
sequence databases revealed no other possible candidate
Fig. 3 – Specific binding of [3H]-2-BFI to rabbit brain creatine
kinase (B-CK) and rabbit whole brain membranes (rabbit WB;
control) with or without BU99006 (10 μM) pre-treatment. The
specific binding to the control (568.8±116.5 fmol mg
protein−1, n=9) and B-CK (2329.5±814.8 fmol mg protein−1,
n=7) was abolished after pre-treatment with BU99006
(Student's t-test, *P<0.04 and **P<0.03 respectively, n=4).
These data represent mean±SEM, n=4–9.
Fig. 2 – (A) I2 binding proteins from rabbit brain isolated using
a 2-BFI affinity column (lane B), molecular markers (lanes A
and C) and proteins eluted from the control (blank) column
(D), in which 2-BFI link was absent. Proteins were separated
by SDS-PAGE (12%) and gels were stained with Coomassie
Blue. As expected, a strong band at ~45 kDa and a few other
weaker bands were detected. This ~45 kDa protein was
absent from proteins eluted from the control column
indicating that it specifically bound to the 2-BFI affinity
column. The proteins eluted from the 2-BFI affinity column
were transferred onto PVDF membranes and the ~45 kDa
band was subjected to protein sequencing. (B) Complete
match of N-terminal protein sequences (10 amino acids) of
the ~45 kDa I2 binding protein and rabbit brain creatine
kinase (EC 2.7.3.2). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web
version of this article.)
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the most probable protein for this isolated protein (∼45 kDa)
to be rat brain creatine kinase.
2.2. [3H]-2-BFI binding to B-CK
Radioligand binding centrifugation assay was performed
using [3H]-2-BFI (5 nM) in order to determine and compare
the I2 binding capacity of purified rabbit B-CK and rabbit whole
brain P2 membrane preparation. Rabbit B-CK was able to
specifically bind to [3H]-2-BFI (2330±815 fmol mg protein−1,
n=7), where the specific binding was determined using
another selective I2 ligand, BU224 (10 μM) (Fig. 3). These data
indicate specific binding of the two selective I2 ligands to an
apparent I2 site on this enzyme. The specific I2 binding was
approximately 4 fold higher in B-CK than in rabbit whole brain
P2 membrane. Pre-treatment with the irreversible I2 ligand,BU99006 (10 μM), significantly attenuated the specific I2
binding in both rabbit B-CK and rabbit whole brain P2
membranes (Student's t-test, P<0.04 and P<0.03 respectively),
indicating that I2 sites occupied by [3H]-2-BFI were displaced
by BU99006 due to its affinity also at the I2 sites. These data
strongly support the existence of an I2 binding site on B-CK.
2.3. Effects of I2 ligands on B-CK activity
TheactivityofB-CKwasmeasured in thepresenceor absenceof I2
ligands (1–20 μM; pre-incubation) using phosphocreatine (0–
35 mM) as the substrate. There were no apparent changes in B-
CK activity in the presence of 2-BFI, BU224, harmane, agmatine or
amiloride, all of which have been reported to have affinity at I2
sites (data not shown). However, BU99006 inhibited the B-CK
activity in a concentration-dependent manner, with the reduc-
tions in the apparent Vmax by 8%, 10% and 16% at 5, 10 and 20 μM,
respectively. These data indicate that the inhibition of B-CK
activity by BU99006 at the tested concentrations is non-compe-
titive (Fig. 4), which is consistentwith the pharmacological profile
of this compound determined previously (Tyacke et al., 2002).
2.4. Molecular modelling of I2 ligands docking to B-CK
crystal structure
Currently, the only B-CK crystal structure available is that
from chicken (Protein Data Bank ID (PDB): 1QH4). Chicken B-CK
demonstrates∼90%homologywith rat and rabbit brain B-CKs,
and thus this was considered suitable for use in our molecular
modelling studies. The I2 binding domain on B-CK was
predicted by molecular modelling using the SiteFinder option
within MOE. Outside the active site, the top ranking binding
site of chicken B-CK was a pocket adjacent to the active site
encompassing amino acid residues Thr71, Val72, Val75,
Leu201, Leu202, Cys283 and Ser285 amongst others.
Fig. 4 – Dose-dependent inhibition of B-CK activity by
BU99006 (5, 10 and 20 μM; pre-incubation), using
phosphocreatine (0–35 mM) as the substrate. The data show
mean percentage control to Vmax±SEM, n=4.
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and BU99006, in their protonated form, in the site encom-
passing Cys283definedbyMOE. Both structures docked readily
to this site (illustrated for BU99006 in Fig. 5). The proximity of
the 2-BFI and BU99006 structures to Cys283 suggests that this
nucleophilic residue could be responsible for the covalent
interaction with BU99006. Covalent attachment of BU99006 to
Cys283, followed by minimization, led to partial occupation of
the enzyme active site (data not shown), which could explain
the results from the pharmacological studies where this
compound inhibited B-CK activity.Fig. 5 – BU99006 docking to a crystal structure of the catalytic sit
residues in proximity to BU99006 (centre) were labelled including
is projected away from Cys283 in this illustration but the dynami
within the reach of Cys283 forming a covalent bond. Also, it is po
exit of BU99006 to the binding pocket. 2-BFI, which shares the sam
reversibly binds to this same pocket.3. Discussion
The present study reports the identification of a ∼45 kDa
imidazoline binding protein as brain creatine kinase (B-CK,
43 kDa, EC 2.7.3.2); this success was made possible largely due
to the use of an affinity column generated with a highly
selective I2 ligand, 2-BFI. This finding was confirmed in both
rabbit and rat, the species most intensively studied for I2
binding sites. We demonstrated that B-CK showed a high I2
binding capacity and this specific binding was abolished by
pre-treatmentwith an irreversible I2 selective ligand, BU99006.
The activity of B-CK was inhibited by BU99006 and the
molecular modelling predicted, with high probability, a
binding pocket adjacent to the active site of B-CK. Our data
clearly demonstrate the existence of an I2 binding site on B-CK.
Creatine kinase (CK) is a well characterised enzyme that is
particularly important for energy homeostasis in cells. Briefly,
CK transfers a phosphoryl group between ADP and ATP using
creatine as an intermediate; the peptide sequence of CK across
all species is highly conservedwith∼60% homology. There are
two cytosolic isoenzymes, brain (B-) and muscle (M-) CK that
are active in mono- or heterodimers and there are a further
two mitochondrial octameric isoenzymes. Cytosolic B-CK
converts ADP to ATP using phosphocreatine at sites of high
energy demand and also converts ATP to phosphocreatine for
energy storage, whereas mitochondrial creatine kinase pre-
ferentially uses ATP synthesised from oxidative phosphoryla-
tion to convert creatine to phosphocreatine and exports this to
cytoplasm (for a review seeWallimann and Hemmer, 1994). B-
CK is a cytosolic enzyme, but it is often tightly associated toe of chicken brain creatine kinase (PDB: 1QH4). Amino acid
Cys283 (bottom centre). The isothiocyanate group on BU99006
c situations in vivo would allow the BU99006 to flip, making it
ssible that the covalent bonds are formed during the entry or
e structure as BU99006 apart from the isothiocyanate group,
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tightly coupled with membrane bound Na+/K+-ATPase (Blum
et al., 1991) and also, CK has previously been reported to
modulate neurotransmitter release (Dunant et al., 1988).
Therefore, it is possible that a population of B-CK, which is
bound to synaptic vesicles or to plasma membranes in
neurons, is involved in neurotransmitter release as well as in
the maintenance of membrane potential through the Na+/K+
ATPase. Such a population of membrane associated B-CKmay
explain how B-CK, typically a cytosolic soluble protein,
remained in our P2 membrane preparation. There is evidence
that I2 sites are found in plasmamembranes (Heemskerk et al.,
1998) and that I2 ligands elevate monoamine release (Nutt
et al., 1995). To this end, further studies are required to
investigate whether or not I2 ligands modulate neurotrans-
mitter release through B-CK.
It was clear from the present study that B-CK contained a
binding site for 2-BFI and the concentration of 2-BFI used has
previously been shown to saturate a high component of I2
sites in rabbit brain (Lione et al., 1996). Under these assay
conditions one could propose [3H]-2-BFI specifically bound to
B-CK with apparent high affinity. This specific binding was
abolished when B-CK was pre-treated with an irreversible I2
ligand, BU99006, further indicating the existence of an I2
binding domain in this enzyme.
The results from the molecular modelling studies suggest
that 2-BFI binds to B-CK in a cleft or a binding pocket adjacent
to the active site. Access to this pocket does not appear to be a
requirement for the catalytic activity of the enzyme suggest-
ing that 2-BFI may occupy this site without interfering or
affecting the activity of B-CK. This could explain the results of
the radioligand binding assay and enzyme activity assay, in
which only the irreversible ligand (BU99006) inhibited B-CK
activity; reversible I2 ligandswith high affinity at I2 sites tested
in this study had no effect on B-CK activity. While docking
studies indicate that BU99006 is able to reversibly occupy this
cleft, results from pharmacological assays demonstrate that it
irreversibly binds to and inhibits B-CK. The most suitable
nucleophile located near the preferred binding pocket is
Cys283. This residue is highly reactive and is conserved in all
known peptide sequences of CK. The importance of Cys283 in
enzyme activity was heavily debated until site-directed
mutagenesis studies showed it plays a role in substrate
binding synergismbut not directly involved in catalysis (Furter
et al., 1993). It is possible that BU99006 acts as an effective
enzyme inhibitor by covalently binding to this residue and
thus disturbing the synergism. In addition, the modelling
studies indicate that the preferred binding mode for BU99006
upon covalent attachment results in partial occupation of the
enzyme active site, which could be another explanation for
the inhibitory effect.
The contradiction between the high affinity of reversible I2
ligands at I2 sites and lack of effects on the B-CK activity draws
attention. We propose below the possible and likely explana-
tions for the discrepancies observed in this study. Firstly, as
described above, our molecular modelling predicted the exis-
tence of an I2 site within B-CK adjacent to the active site, and
that the covalent attachment of BU99006 at the reactive Cys283
leads to a partial occupation of the active site. It is possible that,
without the covalent attachment and the resulting partialoccupation of the active site, an I2 ligand does not act as an
effective enzyme inhibitor at the concentration tested (20 μM).
Secondly, the discrepancies may have arisen because the
concentration of the reversible (competitive) I2 ligands used in
the assay was too low relative to the concentration of the
substrate; and thus the reversible I2 ligands were unable to
compete with the high concentration of the substrate (μM
against mM). Nevertheless, B-CK clearly presents a functional
target for BU99006 and further studies are required to confirm
its functional interaction with other I2 ligands.
Taken together, our data demonstrate that B-CK is an
imidazoline binding protein that contains an I2 binding site.
However, there are likely to be other proteins with I2 binding
sites in brain since the distribution pattern of I2 sites does not
completely mirror that of B-CK (Lione et al., 1998; Sistermans
et al., 1995).
How does the expression profile of ∼45 kDa imidazoline
binding protein compare with that of B-CK? In some neuro-
degenerative disorders changes in expression levels of B-CK
and I2 binding proteins are independently observed. For
example, in Alzheimer's disease, a membrane associated CK
fraction is increased (David et al., 1998), which is consistent
with the increased imidazoline binding protein of ∼45 kDa
detected by immunoblotting in this disorder (García-Sevilla
et al., 1998). Other changes have been observed in animal
models of Huntington's disease; we have previously shown
that the I2 binding site is greatly reduced in Huntington's
disease brains (Reynolds et al., 1996). Animal models suggest
that the ATP synthesis is impaired in Huntington's diseases
(Gines et al., 2003) and the administration of creatine increases
the brain phosphocreatine level eliciting neuroprotective
effects (Matthews et al., 1998). If this impairment of energy
metabolism was due to a depletion of cellular energy stores,
namelyphosphocreatine, then it couldbe speculated that B-CK
expression is altered in this disorder. In addition, it has been
reported that the B-CK level is decreased in the brain of
schizophrenics (Burbaeva et al., 2003). To date, the relation-
ships between I2 sites and schizophrenia remain unknown;
however, investigations into possible modulations in the
density of I2 sites and/or possible effects of I2 ligands in this
disorder would make interesting studies.
To what extent can the actions of I2 ligands be explained
through an interaction with B-CK? B-CK is prominently
expressed in neurons and it has been shown to influence
membrane potentials and neurotransmitter release (Dunant
et al., 1988). This could explain the mechanism by which I2
ligands may affect dopamine, 5-HT and noradrenaline release
as well as their antidepressant-like actions in rats (Finn et al.,
2003; Nutt et al., 1997). It has been reported that CK is directly
and physically associated with the SUR2A subunit, but not the
Kir6.2 subunit of the cardiac ATP sensitive potassium (KATP)
channels (Crawford et al., 2002). Also, there is evidence that CK
regulates KATP channels in pancreatic β-cells (Krippeit-Drews
et al., 2003) where B-CK is the major CK isoenzyme present.
Interestingly, we know that some I2 and I3 ligands regulate
KATP channels in pancreatic β-cells leading to insulin secre-
tion (Morgan et al., 1999). CK is present in the hypothalamus
including the arcuate nucleus (Ikeda and Tomonaga, 1988)
where the I2 site is highly abundant (Lione et al., 1998), and a
link between B-CK and KATP channels has been suggested to
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responsive (GR) neuronal activity. Hypothalamic GR neurons
increase their firing rate with increased extracellular glucose
levels and KATP channels in the hypothalamic GR neurons
have been strongly suggested to be involved in the appetite
control (Miki et al., 2001). Preliminary studies have shown that
2-BFI blocks KATP channels on hypothalamic GR neurons
(personal communication with Professor M. Ashford, Univer-
sity of Dundee, U.K.). This may provide an explanation for the
acute stimulation of eating induced by I2 ligands and the
potassium sensitivity of I2 binding (Hudson et al., 2001).
Undeniably, these hypotheses need to be examined thoroughly
in future studies. In addition, further investigations should
determine whether or not the changes in the level of I2 binding
sites found in conditions such as schizophrenia, Huntington's
disease, depression and opiate dependence are accompanied
by similar alterations in B-CK expression, as seems to be the
case in Alzheimer's disease.
In conclusion, we report the identity of a ∼45 kDa imidazo-
line binding protein to be brain creatine kinase and this
enzyme possesses an I2 binding site. These striking findings
will undoubtedly contribute to greater understanding of the
effects of I2 ligands in psychiatric disorders and to developing
such ligands as novel therapeutic drugs.4. Experimental procedures
4.1. Materials
PharmaLink™ was purchased from Perbio Science, Cramling-
ton, UK. Rabbit B-CK and protease inhibitors cocktail were
purchased from Sigma, Poole, UK. Microcep™ and Nanoceps™
were purchased from Pall Life Sciences, Portsmouth, UK.
Coomassie Brilliant Blue R-250 was obtained from Bio-Rad
Laboratories, Hemel Hempstead, UK. 2-(2-benzofuranyl)2-
imidazoline (2-BFI), 2-(4,5-dihydroimidaz-2-yl)quinoline
(BU224) and 5-isothiocyanato-2-benzofuranyl-2-imidazoline
(BU99006) were kindly synthesised by Dr S. M. Husbands,
University of Bath, U.K. [3H]-2-BFI (specific activity of 70 Ci
mmol−1) was purchased from GE Healthcare, Amersham, U.K.
4.2. Isolation of ∼45 kDa I2 binding protein using a 2-BFI
affinity column
New Zealand White rabbits of either sex (2.5–4 kg) were killed
by a schedule 1 method (overdose of pentobarbitone, i.v.) and
Wistarmale rats (200–250 g) were killed by cervical dislocation.
Whole brains were immediately removed and P2 membranes
were prepared as described previously (Lione et al., 1996).
These P2 membranes were solubilised in 0.5% CHAPS in the
presence of protease inhibitors cocktail. The mixture was
constantly stirred for 2 h on ice followed by centrifugation at
100,000 g for 30 min at 4 °C. A 2-BFI affinity column was
synthesised using PharmaLink™. The PharmaLink™ gel
(10 ml) was incubated with 20 mM 2-BFI in 0.1 M MES, pH
4.7, in the presence of formaldehyde (2.5%v/v final) for 40 h at
40 °C with constant agitation. The gel was then transferred
into a column (2.5×10 cm) and unbound 2-BFI was washed off
with 0.1 M Tris, pH 8.0 (240 ml). Affinity chromatography wasperformed similarly to previously described (Escribá et al.,
1995; Wang et al., 1992). The 2-BFI affinity column was
equilibrated with 0.05% CHAPS (50 ml) prior to the loading of
the solubilised proteins (∼2mgml−1,∼17ml). The columnwas
then washed with 0.05% CHAPS and I2 binding proteins bound
to the 2-BFI affinity column were eluted off with 20 mM
idazoxan. The column was again washed with 0.05% CHAPS
before all the residual proteins were removed by 1MNaCl. The
amount of proteins eluted was monitored by measuring their
absorbance at 280 nm using a UV monitor (Model EM-1 Econo
UV monitor, Bio-Rad Laboratories). The flow rate (1 ml min−1)
was maintained by a peristaltic pump. The fractions eluted
with 20 mM idazoxan (6 ml) were collected and concentrated
using Microcep™ by centrifugation at 5700 g for 90 min.
4.3. SDS-PAGE and electroblotting of I2 binding proteins
onto PVDF membranes
SDS-PAGE (12%) was carried out according to the method of
Laemmli (1970) and the gel was stained with Coomassie Blue.
For protein blotting for the sequencer, previously described
method was used with slight modifications (Dunbar and
Wilson, 1994). Briefly, piperazine diacrylamide was used as a
cross-linker and the gel was pre-run with 50 μM reduced
glutathione for 1 h at 5 mA. The concentrated sample was
mixedwith a loading buffer (62.5 mMTris–HCl (pH 6.8), 3%w/v
SDS, 5% v/v mercaptoethanol, 25% v/v glycerol, and 0.05% w/v
bromophenol blue) and heated for 10min at 100 °C to denature
the proteins. The final samples were loaded onto pre-run gel,
which ran at 18 mA. Proteins were blotted onto PVDF
membranes usingMini Trans-Blot® Cell (Bio-Rad Laboratories)
for 2 h at 300 mA.
4.4. N-terminal protein sequencing of isolated I2 binding
protein
The ∼45 kDa band on PVDF membranes was excised then
sequenced using Applied Biosystems Procise sequencer
(Applied Biosystems, Warrington, U.K.), which utilises the
classic Edman degradation procedure.
4.5. Radioligand binding assay
Rabbit B-CK (5 μg) or rabbit whole brain P2 membranes was
incubated with 5 nM [3H]-2-BFI and 0.8 mgml−1 BSA for 30min
at 20 °C in the presence or absence of BU224 (10 μM) to
establish specific binding. The reaction was terminated by the
addition of polyethylene glycol (12.5% final). The sampleswere
mixed well and precipitated proteins were separated from
solution by centrifugation at 11,000 g for 10 min at 4 °C. The
supernatant was discarded and the remaining pellets were
briefly rinsed twice in ice-cold Tris–HCl buffer (50 mM Tris,
1 mM MgCl; pH 7.4). Scintillation fluid (12 ml) was added and
the radioactivity remained in the samples was counted. For
pre-treatmentwith the I2 irreversible ligand, the sampleswere
incubated with BU99006 (10 μM) for 20min at 37 °C followed by
two washes in ice-cold Tris–HCl buffer by repeated centrifuga-
tion at 11,000 g for 5 min using Nanoceps™ before they were
incubated with [3H]-2-BFI and subjected to the above
procedures.
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The protocol used was modified from the methods described
previously (Florini, 1989;Shainbergetal., 1971).Thefinal composi-
tion of the assaymixturewas 20mMglucose, 10mMmagnesium
acetate, 1 mM ADP, 10 mM AMP, 0.4 mM thio-NAD, 10 mM
dithiothreitol, 0.5 U/ml hexokinase, 1 U/ml glucose-6-phosphate
dehydrogenase and a range of phosphocreatine concentrations
between 0 and 35mM, all in 0.1Mglycylglycine, pH 6.75. Rabbit B-
CKwas pre-treatedwith various I2 ligands (1–20 μM) for 20min at
37 °C before it was added to the assaymixture. The absorbance at
405 nm was measured for obtaining the initial velocities at 25 °C
over 50 min using a 96 well plate reader. The results were
analysed and graphs were created using GraphPad Prism 3.0.
4.7. Molecular modelling of the interaction between I2
ligands and B-CK crystal structure
The crystal structure (PDB: 1QH4) of chicken brain B-CK was
utilised for the modelling studies. Hydrogens were added and
minimised using the MMFF94 force field implemented within
MOE (Chemical Computing Group, 2003.02) and keeping all
other atoms fixed. 2-BFI and BU99006 were drawn using the
Build option of MOE, keeping the imidazoline ring protonated
and minimised using the MMFF94 force field.
2-BFI and BU99006 were docked to 1QH4 using GOLD (CCDC
Software Ltd) with the GOLD Score Fitness Function. In
addition, based on the reversibly docked structure with
BU99006, we simulated covalent bond formation between
Cys283 and the isothiocyanate group of BU99006 and the
resulting modified protein was minimised using the MMFF94
forcefield. In this latter minimization step, only BU99006 and
residues having an atom within 3 Angstroms of Cys283 were
left flexible, all others were fixed.Acknowledgments
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